Search Results - "Amin, Asna"

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 by Peoples, George E, Holmes, Jarrod P, Hueman, Matthew T, Mittendorf, Elizabeth A, Amin, Asna, Khoo, Steven, Dehqanzada, Zia A, Gurney, Jennifer M, Woll, Michael M, Ryan, Gayle B, Storrer, Catherine E, Craig, Dianna, Ioannides, Constantin G, Ponniah, Sathibalan

“…Purpose: E75 is an immunogenic peptide from the HER2/ neu protein, which is overexpressed in many breast cancer patients. We have conducted two overlapping E75…”
Get full text

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine by HOLMES, Jarrod P, BENAVIDES, Linda C, PONNIAH, Sathibalan, PEOPLES, George E, GATES, Jeremy D, CARMICHAEL, Mark G, HUEMAN, Matthew T, MITTENDORF, Elizabeth A, MURRAY, James L, AMIN, Asna, CRAIG, Dianna, VON HOFE, Eric

“…HER-2/neu is overexpressed in breast cancer and is the source of immunogenic peptides. CD4(+) T-helper peptides for HER-2/neu are being evaluated in vaccine…”
Get full text

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial by Patil, Ritesh, MD, Clifton, Guy T., MD, Holmes, Jarrod P., MD, Amin, Asna, MD, Carmichael, Mark G., MD, Gates, Jeremy D., MD, Benavides, Linda H., MD, Hueman, Matthew T., MD, Ponniah, Sathibalan, PhD, Peoples, George E., MD, FACS

“…Background We have treated disease-free breast cancer patients with an HER2/ neu -derived peptide, E75, as an adjuvant vaccine. E75 was originally described as…”
Get full text

Murine HIP/L29 Is a Heparin-binding Protein with a Restricted Pattern of Expression in Adult Tissues by Hoke, David E., Regisford, E. Gloria C., Julian, JoAnne, Amin, Asna, Bègue-Kirn, Catherine, Carson, Daniel D.

“…Heparin/heparan sulfate (Hp/HS)-binding proteins are implicated in a variety of cell biological processes including cell adhesion, modulation of blood…”
Get full text

Fatal ischemic proctitis in a patient with a history of an aortobi-iliac interposition graft by Bandera, Bradley C, Burgess, Pamela, Strode, Matthew, Sparks, Preston, Amin, Asna

Get more information

Patients requiring dialysis are not at risk of greater complication after carotid endarterectomy by Amin, Asna, Golarz, Scott, Scanlan, Bradford, Hashemi, Homayoun, Mukherjee, Dipanker

“…Stroke is a leading cause of disability and the third leading cause of death. Landmark studies have demonstrated that carotid endarterectomy (CEA) reduced the…”
Get more information

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 by Amin, Asna, Benavides, Linda C., Holmes, Jarrod P., Gates, Jeremy D., Carmichael, Mark G., Hueman, Matthew T., Mittendorf, Elizabeth A., Storrer, Catherine E., Jama, Yusuf H., Craig, Dianna, Stojadinovic, Alex, Ponniah, Sathibalan, Peoples, George E.

“…Background E75, a HER2/ neu immunogenic peptide, is expressed in breast cancer (BCa). We have performed clinical trials of E75 + GM-CSF vaccine in…”
Get full text

Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study by Stojadinovic, Alexander, Mittendorf, Elizabeth A, Holmes, Jarrod P, Amin, Asna, Hueman, Matthew T, Ponniah, Sathibalan, Peoples, George E

“…Ongoing cancer vaccine trials are limited by the inability of immunologic assays to monitor clinically relevant surrogates of response. Recent advances in the…”
Get full text

Breast cancer screening compliance among young women in a free access healthcare system by Amin, Asna, Shriver, Craig D., Henry, Leonard R., Lenington, Sarah, Peoples, George E., Stojadinovic, Alexander

“…Background and Objectives To examine mammographic screening compliance among young military healthcare beneficiaries and to examine factors related to one time…”
Get full text

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients : U.S. Military Cancer Institute Clinical Trials Group Study 1-01 and 1-02 by PEOPLES, George E, HOLMES, Jarrod P, STORRER, Catherine E, CRAIG, Dianna, LOANNIDES, Constantin G, PONNIAH, Sathibalan, HUEMAN, Matthew T, MITTENDORF, Elizabeth A, AMIN, Asna, KHOO, Steven, DEHQANZADA, Zia A, GURNEY, Jennifer M, WALL, Michael M, RYAN, Gayle B

Get full text

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine : from US Military Cancer Institute Clinical Trials Group Study 1-01 and 1-02 by AMIN, Asna, BENAVIDES, Linda C, STOJADINOVIC, Alex, PONNIAH, Sathibalan, PEOPLES, George E, HOLMES, Jarrod P, GATES, Jeremy D, CARMICHAEL, Mark G, HUEMAN, Matthew T, MITTENDORF, Elizabeth A, STORRER, Catherine E, JAMA, Yusuf H, CRAIG, Dianna

Get full text